Onk Therapeutics
Biotechnology, Galway Ie, Galway, New York, United States, 11-50 Employees
Phone Number: 35**********
Who is ONK THERAPEUTICS
ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignan...
Read More
-
Headquarters: Galway Ie, Galway, New York, United States
-
Date Founded: 2015
-
Employees: 11-50
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
Does something look wrong? Fix it. | View contact records from ONK THERAPEUTICS
ONK Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ONK Therapeutics
Answer: ONK Therapeutics's headquarters are located at Galway Ie, Galway, New York, United States
Answer: ONK Therapeutics's phone number is 35**********
Answer: ONK Therapeutics's official website is https://onktherapeutics.com
Answer: ONK Therapeutics's revenue is Under $1 Million
Answer: ONK Therapeutics has 11-50 employees
Answer: ONK Therapeutics is in Biotechnology
Answer: ONK Therapeutics contact info: Phone number: 35********** Website: https://onktherapeutics.com
Answer: ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies and solid tumors. The Company was founded in 2015, by Prof. ODwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month